2022 American Transplant Congress
Long-Term Rejection Free Renal Allograft Survival with Fc-Modified Anti-cd154 Antibody Monotherapy in Nonhuman Primates
MGH Center for Transplantation Sciences, Boston, MA
*Purpose: Belatacept is currently the only FDA approved costimulatory blockade (CB) used as an alternative to calcineurin inhibitors in kidney transplantation. However, it has been…2022 American Transplant Congress
Optimization of Human Liver Organoid Model for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
*Purpose: The aim of our project is to develop an in vitro 3D human liver organoid (3D-HLO) model for studying nonalcoholic fatty liver disease (NAFLD)…2022 American Transplant Congress
Comparison of Outcomes of Covid-19 Between Fully Vaccinated and Unvaccinated Kidney Transplant Recipients and According to the Type of M-RNA Vaccine
*Purpose: The evidence regarding the clinical effectiveness of COVID-19 vaccination in kidney transplant (KT) recipients is limited so far. Our purpose is to analyze the…2022 American Transplant Congress
Incidence of Posttransplant Lymphoproliferative Disorder with Belatacept Therapy versus Calcineurin Inhibitor Therapy Alone: Data from One Academic Medical Center
*Purpose: To compare rates of post-transplant lymphoproliferative disorder (PTLD) in patients treated with Belatacept and low-dose calcineurin inhibitors (CNIs) versus patients only treated with standard-dose…2022 American Transplant Congress
Recipient and Center Factors Associated with Immunosuppression Practice Beyond the First Year After Liver Transplantation
1University of Pennsylvania, Philadelphia, PA, 2University of Miami, Miami, FL
*Purpose: To investigate patient and center factors associated with differences in immunosuppression management in the first 5 years after LT.*Methods: A retrospective cohort of 11,326…2022 American Transplant Congress
Selective CD28 Blockade Impacts T Cell Differentiation During Hematopoietic Reconstitution Following Lymphodepletion
*Purpose: Costimulation blockade targeting the CD28 pathway provides improved long-term transplant survival without the nephrotoxicity of calcineurin inhibitors. However, treatment with the CTLA-4Ig fusion protein…2022 American Transplant Congress
Escalating Waitlist Mortality Above MELD 40: A Rationale to Uncap MELD 3.0?
Division of Gastroenterology and Hepatology, Stanford University, Stanford, CA
*Purpose: MELD 3.0 is a recently proposed model that improves upon MELD-Na, incorporating sex and albumin as additional variables, updating existing coefficients and adding relevant…2022 American Transplant Congress
Does ABO/HLA Matching Matter in Uterus Transplantation?
1Baylor University Medical Center, Dallas, TX, 2Baylor Scott and White Dallas, Dallas, TX
*Purpose: Uterus transplantation (UTx) is the most commonly performed vascular composite allograft and is rapidly becoming an accepted treatment for absolute uterine-factor infertility (AUFI). There…2022 American Transplant Congress
Donor-Specific Hyporesponsiveness Following Kidney Transplantation is Explained by Progressive Loss of Donor-Reactive Polyfunctional Cd4+ Effector Memory T Cells
Internal Medicine, Erasmus MC, Rotterdam, Netherlands
*Purpose: After kidney transplantation, donor-specific hyporesponsiveness (DSH) develops which is defined as a lowered response of alloreactive T cells to donor antigen while retaining response…2022 American Transplant Congress
Surging Liver Transplant Rates for Alcohol-Associated Liver Disease May Exacerbate Waitlist Death of Patients with Hepatocellular Carcinoma in MMAT-3 Era
*Purpose: Rates of liver transplantation (LT) for alcohol-associated liver disease (ALD) have increased significantly, in part related to broader acceptance of severe alcohol hepatitis (AH)…
- « Previous Page
- 1
- …
- 128
- 129
- 130
- 131
- 132
- …
- 1683
- Next Page »